Peptide having fibrosis inhibitory activity and composition containing same
The present invention relates to a composition for inhibiting fibrosis and more specifically, to a composition for inhibiting fibrosis, wherein the composition is effective in inhibiting fibrosis of tissue cells by containing a peptide derived from telomerase. The peptide according to the present invention exhibits an effect of inhibiting the progression of various kinds of fibrosis, including fibrosis due to occurrence of cancer, fibrosis due to the administration of chemotherapy anticancer drugs, fibrosis due to the exposure to radiation, or progressive fibrosis of tissues, including a TGF-β signaling procedure, and thus can provide a composition for anti-fibrosis or inhibiting fibrosis and a method for treating diseases due to fibrosis.
1. A method of treating a fibrotic disease comprising administering to a subject in need thereof an isolated peptide of SEQ ID NO: 1, wherein the fibrotic disease is induced by cancer or administration of an anticancer agent.
2. The method according to claim 1 , wherein the fibrotic disease is fibrosis induced by cancer selected from the group consisting of pancreatic cancer, colorectal cancer, stomach cancer, prostate cancer, non-small cell lung cancer, breast cancer, melanoma, and ovarian cancer.
3. The method according to claim 1 , wherein the peptide is administered with a chemotherapeutic agent.
4. The method according to claim 3 , wherein the chemotherapeutic agent is at least one selected from the group consisting of deoxynucleoside analogs and fluoropyrimidines.
5. The method according to claim 4 , wherein the deoxynucleoside analog is gemcitabine, and the fluoropyrimidine is 5-fluorouracil or capecitabine.
6. The method according to claim 1 , wherein the peptide is administered at a daily dose of 0.1 μg/kg to 1 g/kg.
7. A method of treating a fibrotic disease comprising administering to a subject in need thereof a composition comprising an isolated peptide of SEQ ID NO. 1, wherein the fibrotic disease is induced by cancer or administration of an anticancer agent.
8. The method according to claim 7 , wherein the fibrotic disease is fibrosis induced by cancer selected from the group consisting of pancreatic cancer, colorectal cancer, stomach cancer, prostate cancer, non-small cell lung cancer, breast cancer, melanoma, and ovarian cancer.
9. The method according to claim 7 , wherein the method further comprises administration of a chemotherapeutic agent.
10. The method according to claim 9 , wherein the chemotherapeutic agent is at least one selected from the group consisting of deoxynucleoside analogs and fluoropyrimidines.
11. The method according to claim 10 , wherein the deoxynucleoside analog is gemcitabine, and the fluoropyrimidine is 5-fluorouracil or capecitabine.
12. The method according to claim 7 , wherein the composition is administered at a daily dose of 0.1 μg/kg to 1 g/kg.
13. The method according to claim 7 , wherein the composition is administered through oral, rectal, percutaneous, intravenous, intramuscular, intraperitoneal, intramedullar, intrathecal, or subcutaneous routes.
14. The method according to claim 7 , wherein the composition further comprises pharmaceutically acceptable excipients and additives.
15. The method according to claim 14 , wherein the composition inhibits fibrosis of dermal tissue via transforming growth factor-β (TGF-β) signaling process.
16. The method according to claim 15 , wherein the composition is a cosmetic composition.